Benchmark: FDA Reclassification of In Situ Hybridization (ISH) Test Systems for Oncology Therapeutics: Compliance and Implementation Training

Take this benchmark to assess how much you would benefit from taking the course on Compliance and Implementation of the FDA Final Rule on Reclassification of ISH Test Systems for Oncology Therapeutics. In a few minutes, you’ll see where you’re ready and where the course can help you move faster, stay compliant, and support safe, timely oncology care.

What you’ll get:

• A quick read on your readiness for the shift from PMA to 510(k) with special controls
• Clarity on the operational trade‑offs: speed to market vs. depth of validation; flexibility vs. compliance
• Insight into who’s affected—patients, clinicians, and your quality/regulatory teams—and how labeling, evidence, and change control need to evolve
• Specific cues on whether to deepen your strategy in design controls, analytical/clinical performance, labeling alignment, and FDA engagement

Why take it now? The reclassification can reduce burden and expand access—but only if you align studies, labeling, and change management to the special controls. This benchmark spotlights the gaps the course will close so you can make confident, defensible decisions.

Outcome: a concise snapshot of your current approach and the high‑value topics to focus on in the course.